- Home
- NNY vs ACOG Comparison
NNY vs ACOG Comparison
Compare NNY & ACOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNY
- ACOG
- Stock Information
- Founded
- NNY 1987
- ACOG 2000
- Country
- NNY United States
- ACOG Canada
- Employees
- NNY N/A
- ACOG N/A
- Industry
- NNY Investment Managers
- ACOG
- Sector
- NNY Finance
- ACOG
- Exchange
- NNY Nasdaq
- ACOG Nasdaq
- Market Cap
- NNY 158.8M
- ACOG 149.0M
- IPO Year
- NNY N/A
- ACOG N/A
- Fundamental
- Price
- NNY $8.39
- ACOG $6.19
- Analyst Decision
- NNY
- ACOG Strong Buy
- Analyst Count
- NNY 0
- ACOG 1
- Target Price
- NNY N/A
- ACOG $18.00
- AVG Volume (30 Days)
- NNY 50.9K
- ACOG 100.0K
- Earning Date
- NNY 01-01-0001
- ACOG 11-13-2025
- Dividend Yield
- NNY 4.04%
- ACOG N/A
- EPS Growth
- NNY N/A
- ACOG N/A
- EPS
- NNY N/A
- ACOG N/A
- Revenue
- NNY N/A
- ACOG $4,586,341.00
- Revenue This Year
- NNY N/A
- ACOG N/A
- Revenue Next Year
- NNY N/A
- ACOG $101.16
- P/E Ratio
- NNY N/A
- ACOG N/A
- Revenue Growth
- NNY N/A
- ACOG N/A
- 52 Week Low
- NNY $7.58
- ACOG $3.75
- 52 Week High
- NNY $8.87
- ACOG $11.54
- Technical
- Relative Strength Index (RSI)
- NNY 54.83
- ACOG 31.52
- Support Level
- NNY $8.33
- ACOG $6.55
- Resistance Level
- NNY $8.41
- ACOG $6.95
- Average True Range (ATR)
- NNY 0.10
- ACOG 0.45
- MACD
- NNY -0.01
- ACOG -0.04
- Stochastic Oscillator
- NNY 31.82
- ACOG 14.83
About NNY Nuveen New York Municipal Value Fund
Nuveen New York Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from both regular federal and New York state income taxes, by investing in a portfolio of municipal obligations issued by state and local government authorities within the state of New York or certain U.S. territories.
About ACOG Alpha Cognition Inc. Common Stock
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.